BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 446437)

  • 1. Evidence for the epoxide-diol pathway in the biotransformation of mephenytoin.
    Gerber N; Thompson RM; Smith RG; Lynn RK
    Epilepsia; 1979 Jun; 20(3):287-94. PubMed ID: 446437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of mephenytoin metabolites in human urine by gas chromatography and mass spectrometry.
    Lynn RK; Bauer JE; Gordon WP; Smith RG; Griffin D; Thompson RM; Jenkins R; Gerber N
    Drug Metab Dispos; 1979; 7(3):138-44. PubMed ID: 38083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselectivity of the arene epoxide pathway of mephenytoin hydroxylation in man.
    Küpfer A; Lawson J; Branch RA
    Epilepsia; 1984 Feb; 25(1):1-7. PubMed ID: 6420144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin.
    Küpfer A; Brilis GM; Watson JT; Harris TM
    Drug Metab Dispos; 1980; 8(1):1-4. PubMed ID: 6102023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of hydroxylated and demethylated metabolites of mephenytoin in man and laboratory animals using gas-liquid chromatography and high-performance liquid chromatography.
    Küpfer A; James R; Carr K; Branch R
    J Chromatogr; 1982 Oct; 232(1):93-100. PubMed ID: 7142342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of mephenytoin (3-methyl-5-ethyl-5-phenylhydantoin) and its demethylated metabolite by selective ion monitoring.
    Yonekawa W; Kupferberg HJ
    J Chromatogr; 1979 Jun; 163(2):161-7. PubMed ID: 541367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of mephenytoin and ethotoin.
    Troupin AS; Friel P; Lovely MP; Wilensky AJ
    Ann Neurol; 1979 Nov; 6(5):410-4. PubMed ID: 42344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective metabolism of mephenytoin in man.
    Küpfer A; Roberts RK; Schenker S; Branch RA
    J Pharmacol Exp Ther; 1981 Jul; 218(1):193-9. PubMed ID: 7241378
    [No Abstract]   [Full Text] [Related]  

  • 9. Stereochemical aspects of the metabolism of 5-ethyl-5-phenylhydantoin (Nirvanol) in the dog.
    Maguire JH; Kraus BL; Butler TC; Dudley KH
    Drug Metab Dispos; 1981; 9(5):393-401. PubMed ID: 6117436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.
    Schellens JH; van der Wart JH; Breimer DD
    Br J Clin Pharmacol; 1990 Jun; 29(6):665-71. PubMed ID: 2378787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased systemic availability of drugs during acute ethanol intoxication: studies with mephenytoin in the dog.
    Zysset T; Preisig R; Bircher J
    J Pharmacol Exp Ther; 1980 Apr; 213(1):173-8. PubMed ID: 7188964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolic conversion of 3-methyl-5-ethyl-5-phenyl hydantoin (mesantoin) and of 5-ethyl-5-phenyl hydantoin (nirvanol) to 5 - ethyl -5- (p-hydroxyphenyl) hydantoin.
    BUTLER TC
    J Pharmacol Exp Ther; 1956 Jun; 117(2):160-5. PubMed ID: 13332557
    [No Abstract]   [Full Text] [Related]  

  • 13. Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man.
    Küpfer A; Desmond PV; Schenker S; Branch RA
    J Pharmacol Exp Ther; 1982 Jun; 221(3):590-7. PubMed ID: 7086673
    [No Abstract]   [Full Text] [Related]  

  • 14. 5-ethyl-5-phenylhydantoin N-glucuronide, the major urinary metabolite of 5-ethyl-5-phenylhydantoin (Nirvanol) in the dog.
    Maguire JH; Butler TC; Dudley KH
    Drug Metab Dispos; 1982; 10(6):595-8. PubMed ID: 6130906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin.
    May DG; Black CM; Olsen NJ; Csuka ME; Tanner SB; Bellino L; Porter JA; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1990 Sep; 48(3):286-95. PubMed ID: 2401127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
    Küpfer A; Preisig R
    Eur J Clin Pharmacol; 1984; 26(6):753-9. PubMed ID: 6489416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gas chromatographic-mass spectrometric studies on the metabolic fate of ethotoin in man.
    Bius DL; Yonekawa WD; Kupferberg HJ; Cantor F; Dudley KH
    Drug Metab Dispos; 1980; 8(4):223-9. PubMed ID: 6105055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation.
    Küpfer A; Branch RA
    Clin Pharmacol Ther; 1985 Oct; 38(4):414-8. PubMed ID: 4042524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography.
    Meier UT; Kronbach T; Meyer UA
    Anal Biochem; 1985 Dec; 151(2):286-91. PubMed ID: 4096368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.
    Wedlund PJ; Aslanian WS; Jacqz E; McAllister CB; Branch RA; Wilkinson GR
    J Pharmacol Exp Ther; 1985 Sep; 234(3):662-9. PubMed ID: 4032286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.